Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
Clinical and Molecular Hepatology
;
: 234-244, 2019.
Artículo
en Inglés
| WPRIM
| ID: wpr-763404
ABSTRACT
Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral agent is very safe and highly effective (>95% sustained virologic response, SVR) against all genotypes of HCV. Achievement of SVR has been associated with a significant reduction of hepatic decompensation, development of HCC, and liver-related mortality. However, HCC risk is not eliminated even after SVR. The annual incidences of HCC in advanced fibrosis or cirrhosis have been estimated to be up to 2.5–4.5% even in patients with SVR. Therefore, surveillance for HCC is recommended in this high-risk patients. In this review, we will describe the clinical outcomes and the risk of HCC in patients with SVR and suggest who should receive surveillance for HCC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fibrosis
/
Incidencia
/
Factores de Riesgo
/
Mortalidad
/
Hepacivirus
/
Carcinoma Hepatocelular
/
Hepatitis C Crónica
/
Genotipo
/
Hepatitis Crónica
/
Cirrosis Hepática
Tipo de estudio:
Estudio de etiología
/
Estudio de incidencia
/
Estudio pronóstico
/
Factores de riesgo
/
Estudio de tamizaje
Límite:
Humanos
Idioma:
Inglés
Revista:
Clinical and Molecular Hepatology
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS